214 related articles for article (PubMed ID: 21791571)
61. Detectability of hypervascularity in early dynamic PET depends on tracer kinetics: 18 F-FDG versus 68 Ga-DOTATOC in hepatic NET metastasis.
Sänger P; Schierz JH; Marlowe RJ; Freesmeyer M
Liver Int; 2014 Jan; 34(1):161. PubMed ID: 23663248
[No Abstract] [Full Text] [Related]
62. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
[TBL] [Abstract][Full Text] [Related]
63. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME; Schuetz M; Magnaldi S; Weber M; Trattnig S; Karanikas G
Eur Radiol; 2012 Apr; 22(4):938-46. PubMed ID: 22080251
[TBL] [Abstract][Full Text] [Related]
64. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
65. Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC.
Cieciera M; Kratochwil C; Moltz J; Kauczor HU; Holland Letz T; Choyke P; Mier W; Haberkorn U; Giesel FL
Diagn Interv Radiol; 2016; 22(3):201-6. PubMed ID: 27015320
[TBL] [Abstract][Full Text] [Related]
66. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
67. Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging.
Zhang J; Kulkarni HR; Baum RP
Clin Nucl Med; 2020 Feb; 45(2):e125-e127. PubMed ID: 31714276
[TBL] [Abstract][Full Text] [Related]
68. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
69. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
70. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center.
Arslan N; Emi M; Alagöz E; Ustünsöz B; Oysul K; Arpaci F; Uğurel S; Beyzadeoğlu M; Ozgüven MA
Vojnosanit Pregl; 2011 Apr; 68(4):341-8. PubMed ID: 21627019
[TBL] [Abstract][Full Text] [Related]
71. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
[No Abstract] [Full Text] [Related]
72. A five-compartment biokinetic model for
Jeremic MZ; Matovic MD; Krstic DZ; Pantovic SB; Nikezic DR
Med Phys; 2018 Dec; 45(12):5577-5585. PubMed ID: 30291717
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
Schreiter NF; Nogami M; Steffen I; Pape UF; Hamm B; Brenner W; Röttgen R
Eur Radiol; 2012 Feb; 22(2):458-67. PubMed ID: 21904802
[TBL] [Abstract][Full Text] [Related]
74. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
75. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
76. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
77. Yttrium-90 DOTATOC: first clinical results.
Otte A; Herrmann R; Heppeler A; Behe M; Jermann E; Powell P; Maecke HR; Muller J
Eur J Nucl Med; 1999 Nov; 26(11):1439-47. PubMed ID: 10552085
[TBL] [Abstract][Full Text] [Related]
78. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
[TBL] [Abstract][Full Text] [Related]
79. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
80. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
